Search
Caplacizumab
go.drugbank.com/drugs/DB06081ApprovedInvestigationalCaplacizumab was developed by Ablynx, a Sanofi company and FDA approved on February 6, 2019,[L5302] and approved previously by the EU in October 2018 as a combination therapy with plasma exchange and immunosuppression … [A174634]In December 2025, the FDA expanded this indication to include pediatric patients aged 12 years and older with aTTP, in the same combination regimen.[L54958,L54963]
Products: Cablivi 10 mg/1 mL Enjeksiyonluk Çözelti Hazırlamak İçin Toz ve Çözücü, 1 ADET, Cablivi 10 mg/1 mL Enjeksiyonluk Çözelti Hazırlamak İçin Toz ve Çözücü, 7 ADETDihydroergotamine
go.drugbank.com/drugs/DB00320ApprovedInvestigational[L38469] Its use has largely been supplanted by triptans in current therapy due to the class's greater selectivity and more favourable side effect profile. … [A239569] The recently approved Precision Olfactory Delivery technology developed by Impel Neuropharma technology has correlated with an increase of 3-fold in Cmax and 4-fold in AUC despite the solution
Synonyms: (2R,4R,7R)-N-[(1S,2S,4R,7S)-7-benzyl-2-hydroxy-4-methyl-5,8-dioxo-3-oxa-6,9-diazatricyclo[7.3.0.02,6]dodecan-4-yl]-6-methyl-6,11-diazatetracyclo[7.6.1.02,7.012,16]hexadeca-1(16),9,12,14-tetraene-4-carboxamideProducts: Migranal 4 mg/ml - Nasalspray, Dihydergot 2,5 mg - TablettenEmicizumab
go.drugbank.com/drugs/DB13923ApprovedInvestigationalEmicizumab was originated as an improved form of hBS23 and it was approved on November 16, 2017.[A31279, L1016] It was created by Chugai Pharmaceuticals Co.
Products: HEMLIBRA® 30 MG/ML SOLUCION INYECTABLE, HEMLIBRA® 150 MG/ML SOLUCIÓN INYECTABLEAB-201
go.drugbank.com/drugs/DB18629InvestigationalAB-201 is a CAR-NK cell therapy targeted against HER2.[L48340] It is under investigation for the treatment of HER2-positive cancers, including breast and gastric carcinomas.
Synonyms: Ex vivo expanded allogeneic cord blood-derived NK cells that have been genetically modified to express a HER2-directed CAR and secrete IL-15RAPA-201
go.drugbank.com/drugs/DB18446InvestigationalRAPA-201 is an autologous rapamycin-resistant T-cell therapy.
CN-201
go.drugbank.com/drugs/DB18726InvestigationalCN-201 is a humanized anti-CD3/CD19 bispecific antibody.
Norethindrone enanthate
go.drugbank.com/drugs/DB14678InvestigationalMixtures: MESIGYNA 5 MG+50 MG/1 ML ENJEKSIYONLUK COZELTI ICEREN KULLANIMA HAZIR ENJEKTÖRProducts: DEPOCON INJECTION 200 mg/ml, NORISTERAT INJ 200MG/ML (SYRINGE)Tetracaine
go.drugbank.com/drugs/DB09085ApprovedInvestigationalVet approvedTetracaine is an ester local anaesthetic currently available in combination with lidocaine as a cream and patch.
Mixtures: Pliaglis 70 mg/g + 70 mg/g Creme, Pliaglis 70 mg/g + 70 mg/g creamProducts: Pontocaine 5 mg/ml, Inderma MDOlopatadine
go.drugbank.com/drugs/DB00768ApprovedAn ophthalmic solution of olopatadine was approved by the FDA and European Union for the treatment of seasonal and perennial allergic conjunctivitis in 1996 and 2002, respectively. … [A179809] Olopatadine is used for the symptomatic treatment of ocular itching associated with allergic conjunctivitis in ophthalmic formulations and seasonal allergic rhinitis in intranasal formulations
Products: OLOFTAL UD, PALLADA-NS %6.65 MG/ML NAZAL SPREY, 30 MLIdursulfase
go.drugbank.com/drugs/DB01271ApprovedInvestigationalIdursulfase is produced by recombinant DNA technology in a human cell line. … Idursulfase is an enzyme that hydrolyzes the 2-sulfate esters of terminal iduronate sulfate residues from the glycosaminoglycans dermatan sulfate and heparan sulfate in the lysosomes of various cell types
Products: ELAPRASE 2 MG/ML İNFÜZYONLUK ÇÖZELTİ HAZIRLAMAK İÇİN KONSANTRE, 1 ADET, Elaprase (TM) Solution for Intravenous Infusion 2mg/ ml